Search Results - "Raggi, D."

Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis by Raggi, D., Miceli, R., Sonpavde, G., Giannatempo, P., Mariani, L., Galsky, M.D., Bellmunt, J., Necchi, A.

“…The efficacy and safety of a combination of chemotherapeutic agent compared with single-agent chemotherapy in the second-line setting of advanced urothelial…”
Get full text

Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study by Bandini, M., Gibb, E.A., Gallina, A., Raggi, D., Marandino, L., Bianchi, M., Ross, J.S., Colecchia, M., Gandaglia, G., Fossati, N., Pederzoli, F., Lucianò, R., Colombo, R., Salonia, A., Briganti, A., Montorsi, F., Necchi, A.

“…Initial studies of preoperative checkpoint inhibition before radical cystectomy (RC) have shown promising pathologic complete responses. We aimed to analyze…”
Get full text

Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study by Giannatempo, P., Raggi, D., Marandino, L., Bandini, M., Farè, E., Calareso, G., Colecchia, M., Gallina, A., Ross, J.S., Alessi, A., Briganti, A., Montorsi, F., Madison, R., Necchi, A.

“…Pembrolizumab is a new standard of care for patients with platinum-treated, metastatic urothelial carcinoma (UC). Nab-paclitaxel is active in advanced UC. In…”
Get full text

Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes by Giannatempo, P., Greco, T., Mariani, L., Nicolai, N., Tana, S., Farè, E., Raggi, D., Piva, L., Catanzaro, M., Biasoni, D., Torelli, T., Stagni, S., Avuzzi, B., Maffezzini, M., Landoni, G., De Braud, F., Gianni, A.M., Sonpavde, G., Salvioni, R., Necchi, A.

“…After a comprehensive review and meta-analysis, radiotherapy and chemotherapy appeared to be similarly effective overall in clinical stage (CS) IIA and IIB…”
Get full text

Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial by Necchi, A., Lo Vullo, S., Giannatempo, P., Raggi, D., Calareso, G., Togliardi, E., Crippa, F., Pennati, M., Zaffaroni, N., Perrone, F., Busico, A., Colecchia, M., Nicolai, N., Mariani, L., Salvioni, R.

“…Therapeutic options for patients with chemoresistant germ cell tumors (GCTs) are limited. Pazopanib is a selective tyrosine kinase inhibitor with distinct…”
Get full text

Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial by Marandino, L, Raggi, D, Calareso, G, Alessi, A, Colecchia, M, Martini, A, Briganti, A, Montorsi, F, Madison, R, Ross, J S, Necchi, A

“…Durvalumab and cabozantinib have shown single-agent activity in patients with metastatic urothelial carcinoma (UC). ARCADIA is a phase 2 study evaluating their…”
Get full text

PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial by Necchi, A., Giannatempo, P., Mariani, L., Farè, E., Raggi, D., Pennati, M., Zaffaroni, N., Crippa, F., Marchianò, A., Nicolai, N., Maffezzini, M., Togliardi, E., Daidone, M. G., Gianni, A. M., Salvioni, R., De Braud, F.

“…Summary Despite a compelling preclinical rationale for the use of anti-angiogenic drugs in urothelial cancer (UC), short-living responses have been observed in…”
Get full text

Comprehensive biomarker analyses and updated results of PURE-01 study: Neoadjuvant pembrolizumab (pembro) in muscle-invasive urothelial bladder carcinoma (MIBC) by Necchi, A., Briganti, A., Raggi, D., Luciano, R., Colecchia, M., Massa, S., Giannatempo, P., Colombo, R., Gallina, A., Salvioni, R., Mortarini, R., Montorsi, F., Madison, R., Ali, S.M., Ross, J.S., Chung, J., Anichini, A.

Get full text

Combination of baseline LDH, performance status and age to identify solid tumor patients with higher probability of response to anti-PD1 and PDL1 monoclonal antibodies by Cona, M.S., Lecchi, M., Damian, S., Del Vecchio, M., Cimminiello, C., Cresta, S., Duca, M., Necchi, A., Signorelli, D., Poggi, M., Raggi, D., Ratta, R., Verderio, P., de Braud, F.G.M., Di Nicola, M.

Get full text

Clinical significance of early circulating tumor cells (CTC) changes, analyzed by AdnaTest, in patients (pts) receiving first-line methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy (CT) for metastatic urothelial cancer (UC) by Necchi, A, Fina, E, Giannatempo, P, Colecchia, M, Raggi, D, Daidone, M.G, Cappelletti, V

“…An abstract of a study by Necchi et al on the clinical significance of early circulating tumor cells (CTC) changes, analyzed by AdnaTest, in patients receiving…”
Get full text

Hyperprogression during immuno-checkpoint inhibitors (ICIs): A clinically significant problem? by Farè, E., Sdao, S., Damian, S., Cresta, S., Del Vecchio, M., Di Bartolomeo, M., Di Guardo, L.A., Duca, M., Indini, A., Necchi, A., Niger, M., Prisciandaro, M., Procopio, G., Raggi, D., Verzoni, E., Pruneri, G., Di Nicola, M., de Braud, F.G.M.

Get full text

Administration of high-dose chemotherapy with stem cell support in patients 40 years of age or older with advanced germ cell tumours: a retrospective study from the European Society for Blood and Marrow Transplantation database by Necchi, A, Lo Vullo, S, Rosti, G, Badoglio, M, Giannatempo, P, Raggi, D, Secondino, S, Mariani, L, Lanza, F, Pedrazzoli, P

Get full text

High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study by Necchi, A., Mariani, L., Di Nicola, M., Lo Vullo, S., Nicolai, N., Giannatempo, P., Raggi, D., Farè, E., Magni, M., Piva, L., Matteucci, P., Catanzaro, M., Biasoni, D., Torelli, T., Stagni, S., Bengala, C., Barone, C., Schiavetto, I., Siena, S., Carlo-Stella, C., Pizzocaro, G., Salvioni, R., Gianni, A.M.

“…In the late 1990s, the use of high-dose chemotherapy (HDCT) and stem-cell rescue held promise for patients with advanced and poor prognosis germ-cell tumors…”
Get full text

Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes by Necchi, A., Nicolai, N., Mariani, L., Raggi, D., Farè, E., Giannatempo, P., Catanzaro, M., Biasoni, D., Torelli, T., Stagni, S., Milani, A., Piva, L., Pizzocaro, G., Gianni, A.M., Salvioni, R.

“…Since 1985, we introduced a modified combination of etoposide, ifosfamide, and cisplatin (PEI) as second-line therapy of adult male germ cell tumors with the…”
Get full text

Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy by Necchi, A, Pennati, M, Zaffaroni, N, Landoni, E, Giannatempo, P, Raggi, D, Schwartz, L H, Morosi, C, Crippa, F, Farè, E, Nicolai, N, Lanocita, R, Sava, T, Sacco, C, Messina, C, Ortega, C, De Braud, F G, Salvioni, R, Daidone, M G, Gianni, A M, Mariani, L

“…Background: Pazopanib achieved the end point of clinical activity in pretreated patients with urothelial cancer in a single-group, phase 2 trial. The objective…”
Get full text

Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party by Necchi, A, Miceli, R, Bregni, M, Bokemeyer, C, Berger, L A, Oechsle, K, Schumacher, K, Kanfer, E, Bourhis, J H, Massard, C, Laszlo, D, Montoro, J, Flechon, A, Arpaci, F, Secondino, S, Wuchter, P, Dreger, P, Crysandt, M, Worel, N, Kruger, W, Ringhoffer, M, Unal, A, Nagler, A, Campos, A, Wahlin, A, Michieli, M, Sucak, G, Donnini, I, Schots, R, Ifrah, N, Badoglio, M, Martino, M, Raggi, D, Giannatempo, P, Rosti, G, Pedrazzoli, P, Lanza, F

“…Little is known about the prognostic impact of prior paclitaxel therapy and response to induction chemotherapy defined as the regimen preceding high-dose…”
Get full text

2643 Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (UBC): Updated clinical and translational findings of an open-label, single group, phase 2 study by Necchi, A, Giannatempo, P, Mariani, L, Raggi, D, Nicolai, N, Piva, L, Biasoni, D, Catanzaro, M, Torelli, T, Stagni, S, Calareso, G, Togliardi, E, Colecchia, M, Busico, A, Perrone, F, Pelosi, G, Maffezzini, M, Salvioni, R

Get full text

Interim results of PEANUT: An open-label, single-arm, phase 2 study evaluating pembrolizumab plus nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as salvage therapy for metastatic urothelial carcinoma (UC) by Necchi, A., Raggi, D., Bandini, M., Farè, E., Giannatempo, P., Colecchia, M., Pederzoli, F., Gallina, A., Marandino, L., Calareso, G., Madison, R., Briganti, A., Ross, J., Montorsi, F.

Get full text

Retroperitoneal lymph-node dissection (RPLND) as upfront management in stage II germ-cell tumours: evaluation of safety and efficacy of open and laparoscopic procedures by Nicolai, N., Nazzani, S., Catanzaro, M., Tesone, A., Macchi, A., Torelli, T., Stagni, S., Celso, F., Agostini, E., Cloecchia, M., Avuzzi, B., Lanocita, R., Necchi, A., Raggi, D., Giannatempo, P., Farè, E., Salvioni, R., Biasoni, D.

Get full text

No-response at mpMRI after neoadjuvant pembrolizumab is a proxy of adverse pathological and oncological outcomes in patients treated with radical cystectomy: interim results from the PURE01 study by Basile, G., Bandini, M., Zaffuto, E., Scuderi, S., Pederzoli, F., Marandino, L., Raggi, D., Barletta, F., Gandaglia, G., Fossati, N., Burgio, G., Moschini, M., Zamboni, S., Afferi, L., Comana, S., Briganti, A., Montorsi, F., Colombo, R., Necchi, A., Gallina, A.

Get full text